In States That Won’t Pay for Obesity Drugs, ‘They May as Well Have Never Been Created’
The New York Times
Public employees in West Virginia who took the drugs lost weight and were healthier, and some are despondent that the state is canceling a program to help pay for them.
Joanna Bailey, a family physician and obesity specialist, doesn’t want to tell her patients that they can’t take Wegovy, but she has gotten used to it.
Around a quarter of the people she sees in her small clinic in Wyoming County would benefit from the weight-loss medications known as GLP-1s, which also include Ozempic, Zepbound and Mounjaro, she says. The drugs have helped some of them lose 15 to 20 percent of their weight. But most people in the area she serves don’t have insurance that covers the cost, and virtually no one can afford sticker prices of $1,000 to $1,400 a month.
“Even my richest patients can’t afford it,” Dr. Bailey said. She then mentioned something that many doctors in West Virginia — among the poorest states in the country, with the highest prevalence of obesity, at 41 percent — say: “We’ve separated between the haves and the have-nots.”
Such disparities sharpened in March when West Virginia’s Public Employees Insurance Agency, which pays most of the cost of prescription drugs for more than 75,000 teachers, municipal workers and other public employees and their families, canceled a pilot program to cover weight-loss drugs.
Some private insurers help pay for medications to treat obesity, but most Medicaid programs do so only to manage diabetes, and Medicare covers Wegovy and Zepbound only when they are prescribed for heart problems.
Over the past year, states have been trying, amid rising demand, to determine how far to extend coverage for public employees. Connecticut is on track to spend more than $35 million this year through a limited weight-loss coverage initiative. In January, North Carolina announced that it would stop paying for weight-loss medications after forking out $100 million for them in 2023 — 10 percent of its spending on prescription drugs.
The tech giant pushed back the timeline after spending billions to be on the cutting edge of artificial intelligence.
Practitioners nationwide are striving to do what’s best for children’s health, while staying supportive in the face of mistrust and confusion.
A group of scientists and law enforcement officials are pointing to the role moss can play to help solve crimes.
Blaming chatbots, they are joining an earlier push for better protections by parents who say social media contributed to their children’s deaths.
Partula snails all but vanished from Polynesia after the arrival of a carnivorous foreign snail. But a global alliance of zoos has worked to bring them back.
Though high rates of the disease persist among the nearby Indigenous communities, the Canadian government is weighing rules that may allow energy giants to release treated mining waste into the river system.
A new study offers clues as to how the insects survive flooding as they emerge from a hibernation-like phase every winter.
Scientists studied centuries-old bird feathers from an ancient tomb on the coast, and then traced the origins back to the Amazon.
Blaming chatbots, they are joining an earlier push for better protections by parents who say social media contributed to their children’s deaths.
The agency is proposing allowing other tastes for vapes, like mint, coffees, spices or tea, to appeal to adults. At the same time, illicit candy-flavored types aimed at teenagers have flooded the market.
Dr. Vinay Prasad drew criticism for overriding career scientists and rejecting drugs by companies seeking agency approval.
Researchers have devised a new tool for discerning between naturally occurring viral outbreaks and those resulting from lab accidents.
The artificial intelligence company filed two lawsuits against the Department of Defense, saying it was being punished on ideological grounds.